ImmusanT is focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The company is developing Nexvax2, a therapeutic vaccine for celiac disease, and a companion diagnostic and monitoring tool to improve celiac disease management. ImmusanT's targeted immunotherapy discovery platform can be applied to a variety of epitope-specific autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/22/14 | $12,000,000 | Series B | ||
| 11/14/17 | $40,000,000 | Series C |
ARCH Venture Partners | undisclosed |
